NEWTON, PA — Traws Pharma, Inc. (NASDAQ: TRAW) is set to host a virtual investor event on Monday, March 31, 2025, at 10:00 AM ET, where the company will spotlight its groundbreaking oral treatments for H5N1 bird flu and COVID-19. The event will feature presentations from key leaders, including Dr. Robert R. Redfield, former Director of the U.S. Centers for Disease Control and Prevention (CDC) and current Chief Medical Officer of Traws, alongside Chief Science Officer Dr. C. David Pauza.
The highlight of the event will center on two of the company’s oral small molecule product candidates. Tivoxavir Marboxil, a single-dose CAP-dependent endonuclease inhibitor, is designed to combat the H5N1 bird flu virus and mitigate significant public health threats. The presentation will include data from preclinical and Phase 1 studies, previously shared at the International Conference on Antiviral Research (ICAR) 2025, as well as plans for future discussions with the Food and Drug Administration (FDA).
The event will also feature Ratutrelvir, a main protease inhibitor for COVID-19 treatment that can be administered without the need for ritonavir. This eliminates concerns about ritonavir-related drug interactions and clinical rebound effects, which are associated with potential risks for long COVID. Traws will discuss preclinical and Phase 1 results, also presented at ICAR 2025, and outline their strategy for FDA engagement to advance this promising candidate.
A live Q&A session will follow the formal presentations, offering attendees the opportunity to interact directly with Traws’ leadership team and gain deeper insights into the company’s innovative therapies.
This event underscores Traws Pharma’s commitment to addressing urgent global health needs with cutting-edge antiviral solutions. It marks a significant step forward in the development of treatments that aim to improve patient outcomes and combat pressing public health challenges.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.